Silexion Therapeutics Corp (SLXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,258 | 2,440 | 6,018 | 9,269 | 3,491 |
| Other current assets | 111 | 96 | 49 | 47 | 63 |
| TOTAL | $3,741 | $4,065 | $6,637 | $11,055 | $5,237 |
| Non-Current Assets | |||||
| PPE Net | 20 | 23 | 25 | 26 | 30 |
| Other Non-Current Assets | 485 | 514 | 553 | 533 | 530 |
| TOTAL | $505 | $537 | $578 | $559 | $560 |
| Total Assets | $4,246 | $4,602 | $7,215 | $11,614 | $5,797 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,180 | 2,465 | 787 | 946 | 692 |
| Accrued Expenses | 984 | 850 | 910 | 945 | 659 |
| Other current liabilities | 628 | 560 | 879 | 721 | 628 |
| TOTAL | $3,976 | $4,060 | $2,758 | $2,786 | $2,150 |
| Non-Current Liabilities | |||||
| Long Term Debt | 0 | N/A | 1,568 | 1,540 | 3,190 |
| Other Non-Current Liabilities | 226 | 251 | 286 | 311 | 337 |
| TOTAL | $226 | $251 | $1,854 | $1,851 | $3,527 |
| Total Liabilities | $4,202 | $4,311 | $4,612 | $4,637 | $5,677 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 5,560 | 419 | 333 | 313 | 73 |
| Common Shares | 160 | 46 | 42 | 42 | 8 |
| Retained earnings | -61,450 | -57,899 | -55,166 | -50,754 | -47,492 |
| TOTAL | $44 | $291 | $2,603 | $6,977 | $120 |
| Total Liabilities And Equity | $4,246 | $4,602 | $7,215 | $11,614 | $5,797 |